Showing 12 out of 2273 items
- The HIV Legal Network, PASAN, and a criminologist from Toronto Metropolitan University undertook a study exploring the perspectives of former prisoners, community-based harm reduction workers, and…
- CATIE NewsLenacapavir (Sunlenca) is the first capsid inhibitor approved for HIV treatment. Lenacapavir works in a way that is different from other HIV medications. After initial oral dosing, lenacapavir…
- A video reviewing the different forms of PrEP available, including daily and on-demand PrEP, injectable PrEP and vaginal rings.
- CATIE NewsRates of syphilis have been increasing in many parts of Canada over the past decade. B.C. researchers launched and evaluated a campaign for men who have sex with men. Men who saw the campaign…
- When taken as directed, effective HIV treatment helps people with HIV to live long and healthy lives and avoid passing HIV to others. Treatment should be started as soon as possible after a person is…
- CATIE NewsResearchers analysed the outcomes of a safer opioid supply program in London, Ontario. Participants had 32% fewer hospital emergency visits and 54% fewer inpatient visits. Certain annual healthcare…
- Programming ConnectionThe safer opioid supply (SOS) program provides pharmaceutical opioids as an alternative to the unregulated drug supply for eligible participants, in addition to providing comprehensive primary care.
- Lenacapavir – an emerging drug for HIV treatment and hopefully prevention
- Maturation inhibitor advances into clinical trials